Veritas In Silico

Veritas In Silico Equity

The The Equity of Veritas In Silico (130A.T) as of Nov 2, 2026 is 1.78 B JPY. In the previous year, The Equity was 2.21 B JPY — a change of -19.27% (lower).

Equity

1.78 BJPY

YoY

-19.27%

Last updated:

In 2025, Veritas In Silico's equity was 1.78 B JPY, a -19.27% increase from the 2.21 B JPY equity in the previous year.

The Veritas In Silico Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2021
1.68 B JPY
Jan 1, 2022
1.54 B JPY
Jan 1, 2023
1.58 B JPY
Jan 1, 2024
2.21 B JPY
Jan 1, 2025
1.78 B JPY
The Veritas In Silico Equity history
YEAREquityYoY
1.78 BJPY-19.27%
2.21 BJPY+40.23%
1.58 BJPY+2.14%
1.54 BJPY-8.40%
1.68 BJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Veritas In Silico Stock analysis

What does Veritas In Silico do? Veritas In Silico Inc generates revenue through its ibVIS platform, which provides small molecule drug discovery services targeting mRNA. The company collaborates with pharmaceutical companies on joint drug discovery research to develop mRNA-targeted small molecule drugs. Its primary customers are pharmaceutical companies seeking innovative drug discovery solutions. The business focuses on integrating digital technology, including in silico RNA structural analysis, into the pharmaceutical discovery process. The company's core product, the ibVIS platform, combines in silico RNA structural analysis with drug discovery technology to accelerate the development of small molecule drugs targeting mRNA. This platform is offered as a service to pharmaceutical partners, enabling them to leverage advanced digital tools for more efficient drug discovery. The revenue model is based on contractual agreements with pharmaceutical firms for joint research projects. Veritas In Silico Inc's business model centers on providing specialized technology services to the pharmaceutical industry. The company does not sell physical products but offers its platform as a service for drug discovery. Its target market consists of pharmaceutical companies interested in mRNA-targeted therapies, which represent a growing segment in pharmaceutical research and development. Veritas In Silico is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Veritas In Silico's Equity

Veritas In Silico's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Veritas In Silico's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Veritas In Silico's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Veritas In Silico's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Veritas In Silico’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Veritas In Silico stock

The Equity of Veritas In Silico is 1.78 B JPY in 2025.

The Equity of Veritas In Silico changed from 2.21 B JPY to 1.78 B JPY, representing a -19.27% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Veritas In Silico since 2006 – with annual values, charts, and detailed analysis.

The Equity's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Veritas In Silico historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Veritas In Silico

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Veritas In Silico